Trial Profile
A SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-WAY CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF CHF1535 50/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE) AND THE FREE COMBINATION OF LICENSED BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE IN ASTHMATIC CHILDREN ALREADY TREATED WITH INHALED CORTICOSTEROIDS.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chiesi Farmaceutici
- 29 Apr 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
- 01 Aug 2012 Planned End Date changed from 1 Jun 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 11 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01450774).